Details for Patent: 8,669,245

Which drugs does patent 8,669,245 protect, and when does it expire?

Patent 8,669,245 protects VASCEPA and is included in one NDA.

This patent has seventy-four patent family members in twenty-seven countries.

Summary for Patent: 8,669,245

Title:	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
Abstract:	In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.
Inventor(s):	Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
Assignee:	Amarin Pharmaceuticals Ireland Ltd
Application Number:	US13/908,843
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,669,245
Patent Claim Types: see list of patent claims	Use; Composition;

U.S. Patent 8,669,245: Claim Scope, Vascepa Coverage, Expiration and Patent Landscape

U.S. Patent No. 8,669,245 covers a narrow method of using approximately 4 grams per day of highly purified ethyl eicosapentaenoate, or icosapent ethyl, in statin-treated patients with triglycerides of approximately 200 to 500 mg/dL. The claims require a low-docosahexaenoic-acid composition, continued treatment for at least four weeks, and, in several claims, specified LDL-C levels, cardiovascular-risk status, or lipid outcomes.

The patent is closely aligned with the use of Vascepa, Amarin’s icosapent ethyl product. Its commercial value is concentrated in the patient population associated with the REDUCE-IT cardiovascular-risk-reduction indication rather than in the original severe-hypertriglyceridemia indication. Public patent records report an expiration date in late 2029, subject to any applicable patent-term adjustment or terminal-disclaimer limitation.[1]

What does U.S. Patent 8,669,245 protect?

The patent protects a treatment regimen with five principal limitations:

Limitation	Requirement
Active ingredient	Ethyl eicosapentaenoate, also called icosapent ethyl
Daily dose	About 4 grams
DHA content	Not more than about 4% of all fatty acids
Patient population	Statin-treated patient, generally with triglycerides of about 200 to 500 mg/dL
Treatment duration	At least about four weeks

Claims 1 through 7 require a subject with mixed dyslipidemia on stable statin therapy. Claims 8 through 13 omit “mixed dyslipidemia” from the independent claim but add a composition present in more than one dosage unit and require an LDL-C level of 40 to 100 mg/dL.

The claims are method-of-use claims. They do not principally claim the chemical molecule itself, a generic icosapent ethyl composition in the abstract, or a manufacturing process.

What is the core inventive concept?

The core concept is the use of high-dose, low-DHA EPA ethyl ester in statin-treated patients whose triglycerides remain moderately elevated despite statin therapy.

That distinction matters because the patent does not broadly cover every use of fish oil or omega-3 fatty acids. It targets:

• A purified EPA ethyl ester product;
• A daily dose approximating 4 grams;
• A defined triglyceride range;
• Concomitant statin therapy;
• A composition with minimal DHA;
• A treatment period of at least four weeks.

The low-DHA limitation separates the claimed regimen from mixed EPA/DHA products such as omega-3-acid ethyl esters. DHA-containing products can have different effects on LDL-C and lipid fractions.

How do claims 1 through 13 differ?

Claims 1 through 7

Claim 1 is the principal independent claim. It requires:

1. Mixed dyslipidemia;
2. Stable statin therapy;
3. Baseline fasting triglycerides of about 200 to 500 mg/dL;
4. Daily oral administration;
5. About 4 grams of ethyl eicosapentaenoate;
6. No more than about 4% DHA or DHA esters;
7. Treatment for at least about four weeks.

Claims 2 through 7 narrow the population or add outcome limitations.

Claim	Additional limitation
1	Base regimen and patient population
2	Coronary heart disease or a coronary heart disease risk equivalent
3	LDL-C of 40 to 100 mg/dL before treatment
4	LDL-C reduction after four weeks
5	Reduction in one or more listed lipid or inflammatory markers after LDL-C reduction
6	Reduction in one or more listed lipid or inflammatory markers
7	Composition is present in one or more dosage units

Claims 5 and 6 refer to reductions in non-HDL-C, VLDL-C, Lp-PLA2, apolipoprotein B, total cholesterol, HDL-C or VLDL-TG. Because these claims depend on claim 1, they retain all of claim 1’s population, dose, composition and duration requirements.

Claims 8 through 13

Claim 8 is a second independent claim. It requires:

• Stable statin therapy;
• Baseline fasting triglycerides of about 200 to 500 mg/dL;
• LDL-C of 40 to 100 mg/dL;
• Daily oral administration;
• About 4 grams of ethyl eicosapentaenoate;
• No more than about 4% DHA or DHA esters;
• More than one dosage unit;
• At least four weeks of treatment.

Claims 9 through 13 add coronary heart disease or a risk equivalent, mixed dyslipidemia, LDL-C reduction and lipid-marker reductions.

The most commercially relevant difference is that claim 8 expressly requires more than one dosage unit. A four-capsule, 1-gram-per-capsule regimen would ordinarily satisfy the dosage-unit structure if the other claim limitations are met.

Does the patent cover Vascepa?

Vascepa is icosapent ethyl, a highly purified ethyl ester of EPA. The FDA-approved 1-gram capsule contains 1 gram of icosapent ethyl and is administered at a total daily dose of 4 grams for the relevant indications.[2]

Vascepa characteristic	Relevance to Patent 8,669,245
Active ingredient	Matches ethyl eicosapentaenoate
Daily dose	Matches approximately 4 grams
Dosage form	Four 1-gram capsules can satisfy multiple-dosage-unit language
DHA level	Consistent with the low-DHA limitation
Statin use	Relevant to the cardiovascular-risk-reduction indication
Triglyceride range	Matches the 200 to 500 mg/dL population described in the claims
Duration	Matches treatment of at least four weeks

The patent does not cover every Vascepa prescription. Infringement depends on the approved or promoted indication, the patient’s baseline laboratory values, statin status, dose, composition and treatment duration.

A patient with triglycerides above 500 mg/dL may fall outside the principal claim range. A patient taking less than approximately 4 grams per day may also fall outside the claims. A patient not receiving stable statin therapy would present a separate non-infringement issue for claims 1 through 7 and claim 8.

What FDA indications overlap with the patent?

The FDA originally approved Vascepa in 2012 as an adjunct to diet for adults with triglyceride levels of at least 500 mg/dL. That indication was directed to severe hypertriglyceridemia and did not fully correspond to the 200-to-500 mg/dL population in Patent 8,669,245.[2]

In 2019, FDA approved Vascepa as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adults with elevated triglycerides and established cardiovascular disease or diabetes plus additional cardiovascular risk factors.[3]

The 2019 indication closely corresponds to the patent’s requirements for:

• Statin therapy;
• Moderate baseline triglycerides;
• Cardiovascular disease or a risk equivalent;
• A high-dose, low-DHA EPA product.

The patent’s claims are therefore more closely connected to the cardiovascular-risk-reduction label than to the original severe-hypertriglyceridemia label.

What is the Orange Book status of U.S. Patent 8,669,245?

The FDA Orange Book is the controlling source for patents submitted for listing against an approved small-molecule drug product. Patent listings can change over time through listing, delisting, expiration, litigation notifications and regulatory updates.[4]

The Vascepa Orange Book estate has included multiple Amarin patents directed to composition, purity, dosage and methods of use. The principal publicly reported Vascepa patents include U.S. Patent Nos. 8,293,728, 8,357,677, 8,367,675, 8,372,849, 8,598,227, 8,741,948, 8,889,726 and 9,700,499.[5]

Patent 8,669,245 should be evaluated separately from the patents that Amarin asserted in the principal generic litigation. Its claims are directed to a specific clinical-use regimen and are not interchangeable with patents claiming the composition, purity or capsule formulation.

A patent’s absence from a particular litigation complaint does not establish that it is invalid, unenforceable or commercially irrelevant. It may reflect listing decisions, claim scope, litigation strategy, the asserted ANDA indications, or an assessment that another patent provides stronger coverage.

When does Patent 8,669,245 lose exclusivity?

Public patent records identify an expiration date in late 2029 for the patent family associated with U.S. Patent 8,669,245.[1] The practical exclusivity date must be determined from the issued patent, USPTO term data and any terminal disclaimer or patent-term adjustment.

The relevant timeline is:

Event	Date
Earliest reported priority	December 30, 2008
Patent grant	March 11, 2014
Original Vascepa approval	July 26, 2012
Cardiovascular-risk-reduction approval	December 13, 2019
Reported patent expiration	Late 2029
NCE exclusivity	Expired before the principal generic litigation

The FDA’s five-year new chemical entity exclusivity did not protect Vascepa from generic competition after the initial exclusivity period. Later protection depended mainly on patents and regulatory exclusivities associated with the approved indications.

What patents compete with U.S. Patent 8,669,245 in the Vascepa estate?

The Vascepa estate can be divided into four functional groups.

Composition and purity patents

These patents address high-purity EPA ethyl ester compositions and restrictions on DHA or other omega-3 components. They are important because a generic product containing materially higher DHA levels may avoid some claims but would not necessarily be therapeutically or regulatorily interchangeable with Vascepa.

Dosage and capsule patents

These patents address the amount of icosapent ethyl per capsule, daily dosing, capsule configurations and pharmaceutical presentation. They can create barriers even where a generic manufacturer can make the active ingredient.

Method-of-use patents

Patent 8,669,245 is in this category. Method claims focus on the patient population, lipid levels, concomitant statin therapy, dose and clinical outcomes.

Cardiovascular-risk-reduction patents

The later Vascepa estate included patents associated with use in cardiovascular-risk-reduction populations. These patents were central to Amarin’s efforts to protect the 2019 label expansion.

Which companies challenged Vascepa patents?

Hikma Pharmaceuticals USA Inc. and Dr. Reddy’s Laboratories Ltd. were among the principal generic challengers. Their ANDA filings included Paragraph IV certifications against Amarin patents covering Vascepa.[6]

Amarin sued generic defendants in the U.S. District Court for the District of Delaware. In Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., the district court held asserted Vascepa patent claims invalid for obviousness. The Federal Circuit affirmed the district court’s judgment.[6,7]

The litigation outcome reduced the enforceability of the asserted Vascepa patents against the challenged generic products. It did not automatically adjudicate every claim of every Vascepa-related patent, including every claim of Patent 8,669,245.

What was the Paragraph IV impact?

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable or not infringed. The filing can trigger patent litigation and a 30-month stay of FDA approval under the Hatch-Waxman Act, subject to statutory exceptions.[8]

For Vascepa, the commercial significance of the Paragraph IV challenges was substantial because:

• The drug had a high-value expanded indication;
• The approved product was a small-molecule capsule;
• Generic manufacturers could pursue ANDA approval;
• The asserted patents included method and composition claims;
• The generic products could potentially use a label carve-out for protected indications.

Can generic icosapent ethyl enter without infringing the patent?

Yes. A generic launch can avoid or reduce infringement exposure through several routes:

1. A label limited to the severe-hypertriglyceridemia indication;
2. A section viii statement carving out the cardiovascular-risk-reduction indication;
3. A product composition that does not satisfy the low-DHA limitation;
4. A dosage regimen outside the claimed approximately 4-gram daily treatment;
5. A patient population outside the claimed triglyceride or LDL-C ranges;
6. A non-infringement position based on the absence of stable statin therapy.

The practical risk is higher where the generic label reproduces the statin-treated, moderate-triglyceride cardiovascular-risk-reduction indication. A label carve-out can reduce induced-infringement risk, but it does not eliminate risk from generic substitution, physician prescribing, pharmacy practices or promotional conduct.

How strong is the patent estate?

Patent 8,669,245 has meaningful claim specificity but limited breadth.

Strength factor	Assessment
Product alignment	Strong for Vascepa and equivalent high-purity icosapent ethyl
Population specificity	Narrow
Dose requirement	Strong product-to-regimen correlation at 4 grams daily
DHA limitation	Useful distinction from mixed EPA/DHA products
Detectability	Moderate; patient lipid data and treatment records are needed
Generic design-around	Moderate to strong through label carve-outs
Litigation resilience	Reduced where overlapping Vascepa claims have been held obvious
Commercial relevance	Highest for the cardiovascular-risk-reduction population

The claims are easier to map to a branded regimen than to prove in every individual prescription. In a method-of-use case, the critical evidence would include the generic label, marketing materials, prescribing information, patient population, dosage instructions and the generic manufacturer’s intended use.

The four-week duration and laboratory thresholds also create proof issues. A patient’s triglycerides and LDL-C can change over time, and stable statin therapy must be established. “About” introduces claim-construction flexibility but does not remove the need to prove substantial conformity with the claimed ranges.

What manufacturing and IP barriers remain?

Manufacturing icosapent ethyl at commercial scale requires control of:

• EPA ethyl ester purity;
• Oxidation and peroxide levels;
• Residual fatty-acid impurities;
• DHA content;
• Capsule fill uniformity;
• Stability and packaging;
• Batch-to-batch composition.

These technical requirements can support regulatory approval and product quality even where patent barriers weaken. They do not independently extend patent exclusivity.

A generic manufacturer can face separate barriers involving analytical methods, supplier qualification, formulation scale-up, bioequivalence and regulatory labeling. The strongest IP barrier is the combined estate, not Patent 8,669,245 viewed in isolation.

How does Patent 8,669,245 compare with Lovaza and other omega-3 products?

Product	Principal omega-3 content	DHA profile	Typical patent distinction
Vascepa	Icosapent ethyl, purified EPA ethyl ester	Minimal DHA	High-purity EPA, 4-gram regimen, cardiovascular-risk population
Lovaza	EPA and DHA ethyl esters	Material DHA content	Mixed omega-3 composition and severe-hypertriglyceridemia use
Epanova	Omega-3 carboxylic acids	EPA/DHA mixture	Different chemical form and formulation
Generic icosapent ethyl	EPA ethyl ester	Intended to match reference product	ANDA, label and patent-certification strategy

Patent 8,669,245 is structurally narrower than a composition patent covering purified icosapent ethyl. It is also more commercially targeted than a patent directed only to severe hypertriglyceridemia.

What is the revenue exposure from generic entry?

Vascepa revenue exposure is concentrated in the cardiovascular-risk-reduction indication because the indication materially expanded the potential treated population and prescription value. Amarin reported approximately $598.3 million in net product revenue in 2020, the first full commercial period after the expanded indication began to affect market demand.[9]

Generic entry can reduce revenue through:

• Lower reimbursed prices;
• Pharmacy substitution;
• Formulary displacement;
• Reduced branded volume;
• Loss of indication-specific prescribing;
• Generic use of the same active ingredient in non-patent-protected populations.

The revenue impact depends on whether generic manufacturers launch with only the severe-hypertriglyceridemia indication or also pursue the cardiovascular-risk-reduction indication.

Key Takeaways

• U.S. Patent 8,669,245 is a method-of-use patent centered on approximately 4 grams per day of low-DHA icosapent ethyl.
• The principal population is statin-treated patients with triglycerides of approximately 200 to 500 mg/dL.
• Claims 2, 3, 8, 9, 10 and 11 add cardiovascular-risk, LDL-C or mixed-dyslipidemia limitations.
• Claims 4 through 6 and 12 through 13 add lipid-response limitations.
• The claims closely track the clinical setting for Vascepa’s cardiovascular-risk-reduction indication.
• The reported patent expiration is in late 2029.
• Generic entry can use indication carve-outs, different labeling or non-infringement positions.
• Hikma and Dr. Reddy’s challenged the broader Vascepa patent estate, and asserted patents in the principal litigation were held invalid for obviousness.
• That litigation result does not, by itself, determine the validity or enforceability of every claim of Patent 8,669,245.
• The commercial value of the patent depends on the combined Vascepa patent estate, FDA labeling, generic label design and pharmacy substitution behavior.

FAQs

Does Patent 8,669,245 cover 1-gram Vascepa capsules?

It can cover a regimen using four 1-gram capsules daily if the patient, composition, statin therapy, triglyceride range and treatment duration satisfy the applicable claim.

Does the patent require a reduction in LDL-C?

Only certain dependent claims require LDL-C reduction. Claims 1 and 8 do not expressly require that clinical result, although they impose the other regimen and patient-population limitations.

Can a product containing DHA infringe Patent 8,669,245?

A product with more than approximately 4% DHA or DHA esters by weight of all fatty acids would have a strong non-infringement position against the express DHA limitation, subject to claim construction and the doctrine of equivalents.

Does treatment of triglycerides above 500 mg/dL fall within the patent?

The principal claims recite baseline fasting triglycerides of approximately 200 to 500 mg/dL. Treatment beginning above that range may fall outside the literal scope of those claims.

Is Patent 8,669,245 a composition patent?

No. The patent’s supplied claims are method claims. They protect administering a specified icosapent ethyl composition to a defined patient population for a specified period.

References

1. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,669,245, methods of treating hypertriglyceridemia.
2. U.S. Food and Drug Administration. (2024). Vascepa (icosapent ethyl) prescribing information.
3. U.S. Food and Drug Administration. (2019, December 13). FDA approves use of drug to reduce risk of cardiovascular events in adults with elevated triglyceride levels.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. Amarin Corporation plc. (2023). Annual report on Form 10-K.
6. Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., No. 19-1879, 2020 WL 6904582 (D. Del. Nov. 24, 2020).
7. Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., 100 F.4th 1359 (Fed. Cir. 2024).
8. Hatch-Waxman Amendments, 21 U.S.C. § 355(j).
9. Amarin Corporation plc. (2021). Annual report on Form 10-K for fiscal year 2020.

Drugs Protected by US Patent 8,669,245

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-001	Jul 26, 2012	AB	RX	Yes	Yes						USE OF VASCEPA TO LOWER TRIGLYCERIDES IN A MIXED DYSLIPIDEMIA ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-002	Feb 16, 2017	AB	RX	Yes	No						USE OF VASCEPA TO LOWER TRIGLYCERIDES IN A MIXED DYSLIPIDEMIA ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY

International Family Members for US Patent 8,669,245

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2443246		301137	Netherlands
European Patent Office	2443246		LUC00226	Luxembourg
European Patent Office	2443246		PA2021522	Lithuania
European Patent Office	2443246		2021C/538	Belgium